Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Rating

Rating methodology
Latest close (chg%)234.18-0.15%
Buy price
238.00
Target price242.00
Sell price229.90
P/E TTM26.81
P/E20.43
Confidence70%
Risk score50/100
AI Summary
Strong fundamentals (earnings, dividend, analyst upgrades) conflict with bearish technicals and overhead resistance at $238-$242. The committee recommends waiting for a confirmed daily close above $238 before initiating a scaled entry, as this validates the bullish thesis while respecting the immediate technical risk.

Alpha Score

0-10
  • Trend（Score 2/10）

    Johnson & Johnson (JNJ) exhibits a bearish technical picture with the stock trading below all key moving averages, showing strong selling pressure and negative momentum indicators, suggesting continued weakness in the short to intermediate term.

  • Valuation（Score 6/10）

    Valuation analysis suggests JNJ is currently undervalued relative to its fair value range of $240-$250. While P/E at 26.85 is reasonable for a stable blue-chip, P/B at 6.93 and P/S at 25.76 are elevated but typical for pharmaceutical companies with intangible assets. Current price of $234.18 sits near the lower end of recent trading range.

  • Financial strength（Score 5/10）
    Financial condition appears stable with moderate leverage. The company has sufficient short-term liquidity but carries significant debt financing. Balance sheet is characteristic of an established industry leader with manageable liquidity and likely sustainable capital structure.
  • Profitability（Score 7/10）
    Johnson & Johnson demonstrates strong and improving profitability with exceptionally high margins in latest quarter, though some metrics may be influenced by one-time events. The company shows solid returns on equity and assets, with modest but positive revenue growth typical for its scale.
  • Sentiment（Score 8/10）
    Johnson & Johnson's overwhelmingly positive news flow, driven by strong Q1 results, dividend hike, and analyst upgrades, supports a buy recommendation with potential for continued price appreciation.
Latest price
$234.18-0.15%
Market cap564.05B
P/E TTM26.81
P/E20.43
Volume8.9M
Turnover2.09B